Many forms of criminal activity generate significant amounts of money. To avoid attracting the attention of law enforcement, criminals must find a way to disguise the source of their ill-gotten funds. That’s the goal of money laundering, which involves criminals engaging in a series of transactions to conceal the criminal origins of their money.

Money laundering involves three stages:

1. A criminal (or those under their direction) introduces funds earned through criminal activity to the financial system.
2. A money launderer (or the criminal themselves) engages in a series of transactions to create layers between the illegal source of the cash they control.
3. The criminal moves laundered money back into the financial system.

The layering process

During the layering stage, the goal is to disconnect the money from the illegal activity that generated it. Generally, the more layers money passes through, the harder it becomes to connect the funds to criminal activity.

The goal of layering is to make the process of tracking money through each layer more difficult to accomplish. Layering can include changing the nature of the assets, i.e. cash, gold, casino chips, real-estate, etc.

Complex layering schemes involve sending the money around the globe using a series of transactions. The more countries the money enters and leaves, the harder it is to uncover the “dirty” source of the money.

Layering and AML

A complex layering scheme makes anti-money laundering (AML) operations challenging. Since they lack jurisdiction overseas, law enforcement must coordinate with their foreign counterparts, which can delay the tracking of the funds while complicating the document trail associated with the funds.

To complicate matters further, criminals often use shell companies, which engage in fraudulent transactions, such as the creation of fake invoices. Once the company receives payment for the fake invoice, those who control the shell company can return the proceeds or send them to another shell company as payment for a subsequent fake invoice.

Layering can involve electronic transactions such as wires and ACHs, paper transactions, and/or manual movement of the funds between countries using covert means. Those laundering the funds may also decide to use non-traditional financial systems, such as Hawala (Middle East), Hundi (India), or Hui Kuan (Hong Kong), which are alternative remittance systems that allow for the movement of money without doing so physically.

Gilead Sciences, Inc. (GILD), a Drug Manufacturers—General business, was a gaining stock in the previous trading session. Gilead Sciences, Inc. (GILD) shares started the day for trading at $77.10 and closed the day at $79.64 with momentum of +2.39%. The increase move in Gilead Sciences, Inc. (GILD) beat the move in the S&P 500 for the day which gained +1.39% in previous trading day.

Gilead Sciences, Inc. (GILD) is focused on the Drug Manufacturers—General sector. This sector has seen some movement from investors in recent months. Bullish investors of Gilead Sciences, Inc. (GILD) will be looking for positive upcoming earnings whereas bearish investors of Gilead Sciences, Inc. (GILD) will be looking for negative earnings. The last time Gilead Sciences, Inc. (GILD) had an earnings surprise was on Qtr Ending 12/19 when they reported $1.10 compared to an estimate of $1.58 which was a difference of -$0.48 resulting in a change of -30.38%. Current earnings estimates are to be released for Current Qtr 03/2020 on Gilead Sciences, Inc. (GILD) and out of 7 Wall Street estimates the average is saying $1.47. The high estimate is saying $1.74 whereas the low estimate is saying $1.33 and the prior year Gilead Sciences, Inc. (GILD) announced earnings at $1.67 a growth rate est. (year over year) of -11.98%.

The market performance of Gilead Sciences, Inc. (GILD) has varied recently. Year to date Gilead Sciences, Inc. (GILD)’s shares are up 22.56%. Over the past 12 weeks Gilead Sciences, Inc. (GILD) is up 24.38% and over the last 4 weeks Gilead Sciences, Inc. (GILD) is up 7.83%. Gilead Sciences, Inc. (GILD) current income statement shows revenue (ttm) of $22.45B. Gross Profit is $17.77B. This puts the current EBITDA of Gilead Sciences, Inc. (GILD) at $6.49B.

Wall street investors might also notice recent changes to stock analyst estimates for Gilead Sciences, Inc. (GILD). The stock is trading with an RSI (relative strength index) of 53.72 indicating Gilead Sciences, Inc. (GILD) is neither overbought nor oversold. Technically, GILD’s short term support levels are around $79.27, $78.28 and $77.36 on the downside. GILDs short term resistance levels are $85.17, $80.98 and $80.27 on the upside. The market cap of Gilead Sciences, Inc. (GILD) is $100.268B and institutions hold 84.00% of the stock. The outstanding share count stands at 1.32B while the short float (shares short) stands at 1.80%.

Stock market research indicates that these earning estimate changes look to be directly correlated with short-term shares prices. The investors can look to capitalize on the basis of ranking. Gilead Sciences, Inc. (GILD) has short term rating of Bullish (0.28), Intermediate rating of Bullish (0.29) and long-term rating of Bullish (0.44) giving Gilead Sciences, Inc. (GILD) an overall rating of Bullish (0.34).

The EPS growth this year on Gilead Sciences, Inc. (GILD) is increased 1.10% and is expected to increase 0.32% next year. However, quarterly earnings (EPS) growth year over year on Gilead Sciences, Inc. (GILD) has increased by 89766.70% and quarterly revenue (Sales) growth year over year stands at 1.40%. Gross margin is detected at 79.20% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Net profit margin (ttm) is 24.00% while return on equity (ttm) is 24.60%.

Recent Developments:

2020-04-23 – Gilead Says Regrets That WHO Prematurely Posted Data Regarding Remdesivir Study.
2020-04-23 – Gilead Antiviral Drug Remdesivir Flops In First Trial – FT.
2020-04-06 – Gilead Sciences And Second Genome Announce Collaboration In Biomarker And Inflammatory Bowel Disease Drug Discovery.
2020-04-05 – Gilead Sciences Says Taking Actions Since January To Rapidly Expand Production, Supply Of Investigational Drug Remdesivir.
2020-03-30 – Gilead Announces Expiration Of Hart-Scott-Rodino Waiting Period For Forty Seven Tender Offer.

About Company:

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide (TAF)-based products Genvoya, Odefsey, Descovy, Biktarvy and Truvada. Total sales from HIV franchise came in at $16.

Paycom Software, Inc. (PAYC), a Software—Application corporation, was a active mover in the prior market session. Paycom Software, Inc. (PAYC) stock opened at $273.62 and closed the day at $272.03 with momentum of +1.19%. This increase movement lagged the S&P 500’s +1.69% gain on the prior market day.

Paycom Software, Inc. (PAYC) is focused on the Software—Application sector. This sector has seen some movement from investors in recent months. Bullish investors of Paycom Software, Inc. (PAYC) will be looking for positive upcoming earnings whereas bearish investors of Paycom Software, Inc. (PAYC) will be looking for negative earnings. The last time Paycom Software, Inc. (PAYC) had an earnings surprise was on Qtr Ending 03/20 when they reported $1.10 compared to an estimate of $1.05 which was a difference of $+0.05 resulting in a change of +4.76%. Current earnings estimates are to be released for Current Qtr 06/2020 on Paycom Software, Inc. (PAYC) and out of 3 Wall Street estimates the average is saying $0.44. The high estimate is saying $0.60 whereas the low estimate is saying $0.28 and the prior year Paycom Software, Inc. (PAYC) announced earnings at $0.67 a growth rate est. (year over year) of -34.33%.

The market performance of Paycom Software, Inc. (PAYC) has varied recently. Year to date Paycom Software, Inc. (PAYC)’s shares are up 2.75%. Over the past 12 weeks Paycom Software, Inc. (PAYC) is down -10.31% and over the last 4 weeks Paycom Software, Inc. (PAYC) is up 22.54%. Paycom Software, Inc. (PAYC) current income statement shows revenue (ttm) of $780.1M. Gross Profit is $648.34M. This puts the current EBITDA of Paycom Software, Inc. (PAYC) at $279.08M.

Wall street investors might also notice recent changes to stock analyst estimates for Paycom Software, Inc. (PAYC). The stock is trading with an RSI (relative strength index) of 62.18 indicating Paycom Software, Inc. (PAYC) is neither overbought nor oversold. Technically, PAYC’s short term support levels are around $1367.66, $1334.96 and $1286.57 on the downside. PAYCs short term resistance levels are $1526.69, $1493.59 and $1432.99 on the upside. The market cap of Paycom Software, Inc. (PAYC) is $15.932B and institutions hold 77.20% of the stock. The outstanding share count stands at 57.87M while the short float (shares short) stands at 7.26%.

Research shows that these earning estimate changes look to be directly correlated with short-term stock prices. The investors can look to capitalize on the basis of ranking. Based on technical analysis, PAYC has short term rating of Bullish (0.47), Intermediate rating of Bullish (0.40) and the long-term rating of Very Bullish (0.51) giving it an overall rating of Bullish (0.46).

The EPS growth this year on Paycom Software, Inc. (PAYC) is increased 32.30% and is expected to increase 24.50% next year. However, quarterly earnings (EPS) growth year over year on Paycom Software, Inc. (PAYC) has increased by 33.10% and quarterly revenue (Sales) growth year over year stands at 21.30%. Gross margin is detected at 85.80% that represents the percent of total sales revenue that the company retains after direct cost of goods sold. Net profit margin (ttm) is – while return on equity (ttm) is -.

Recent Developments:

2020-04-28 – Paycom Software Inc Withdraws Previously Issued Full-Year 2020 Guidance.
2020-03-25 – Paycom Software Says CEO Chad Richison’s FY 2019 Total Compensation Was $21.1 Million – SEC Filing.
2020-02-05 – Paycom Software Q4 Non-GAAP Earnings Per Share $0.86.
2020-01-22 – Paycom Software Set To Join S&P 500.
2019-12-02 – Paycom Software, Inc. Presents at Credit Suisse 23rd Annual Technology Conference, Dec-03-2019 03:30 PM.

About Company:

Headquartered in Oklahoma City, Paycom Software, Inc. is a provider of cloud-based human capital management (HCM) software as a service solution for integrated software for both employee records andtalent management processes. Founded in 1998, the company offers analytics that manages the complete employment life cycle from recruitment to retirement.